Evidence map›Paper›PMID 42787920›Full record

ArticleMethodsX2026

Rapid and efficient generation of multigene-knockout THP-1 cells using a simple CRISPR-Cas9 protocol.

Chihiro Ito, Yuki Kinomura, Kensho Kawagoe, Shinobu Fujii, Toshihiro Fujii, Rikiro Fukunaga

Abstract read
In one paragraph

Article in MethodsX, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chihiro ItoDepartment of Biochemistry, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Nasahara 4-20-1, Takatsuki, Osaka, 569-1094, Japan.
Yuki KinomuraDepartment of Biochemistry, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Nasahara 4-20-1, Takatsuki, Osaka, 569-1094, Japan.
Kensho KawagoeDepartment of Biochemistry, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Nasahara 4-20-1, Takatsuki, Osaka, 569-1094, Japan.
Shinobu FujiiDepartment of Biochemistry, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Nasahara 4-20-1, Takatsuki, Osaka, 569-1094, Japan.
Toshihiro FujiiDepartment of Biochemistry, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Nasahara 4-20-1, Takatsuki, Osaka, 569-1094, Japan.
Rikiro FukunagaDepartment of Biochemistry, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Nasahara 4-20-1, Takatsuki, Osaka, 569-1094, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

THP-1, a widely used human monocytic leukemia cell line, has been described as one of the hard-to-transfect suspension cell lines. Here, we present a rapid and efficient method for generating multiplex gene knockout cells from THP-1 using a simple co-transfection strategy based on the CRISPR-Cas9 system. In this method, THP-1 cells were transfected with a mixture of pX330-based sgRNA plasmids and a small amount of puromycin-resistance plasmid by electroporation, followed by transient selection with high-dose puromycin. This simple method resulted in efficient simultaneous knockout of multiple genes. For genes important for survival and/or cell proliferation, gene-knockout clones may be isolated by the limiting dilution method immediately after puromycin selection.•A simple co-transfection strategy to knock out multiple genes simultaneously in the human monocytic leukemia cell line, THP-1.•Transient selection with high-dose puromycin appeared to be effective for efficient knockout.•In general, knockout efficiency is satisfactory, and polyclonal knockout cells can be used without a cloning step unless the target gene plays a critical role in cell survival or proliferation.

Indexed as

CRISPR-Cas9ElectroporationJun/Fos familyMultiplex gene knockoutTHP-1 cells

Identifiers

PMID42787920
PMCPMC13602318

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.